Recent studies have highlighted the therapeutic potential of LOXL2 inhibition in mouse models of liver fibrosis, suggesting that LOXL2 could be a promising target for treating hepatic fibrosis [206,207]. Here, LOXL2 is linked to Hepatic fibrosis.